Pharma Packaging

Three days to test a capsule filler for phytopharmaceutical and nutraceutical products: a success signed by Italy and Germany joint work! Read the ITALIAN version One of MG2 first goals consists in reaching the customer by providing the best technical solutions. This goal has become even more strategic during the present worldwide spring 2020 crisis, which severely limited the movement of both people and goods. MG2 has successfully overcome this difficulty thanks to remote working technical solutions, chosen among the most consolidated office automation tools.

For this reason, it implemented all the indications provided for by the Shared Protocol on March 14, 2020 between the Government, Trade Unions and Trade Associations. In order to allow its employees and suppliers to access workplaces in compliance with the precautions that the current serious situation requires to adopt.

We as METE PLASTIC INDUSTRY AND CO.INC. give most of the face shields that we produce to those healthcare professionals as a gift What we do is not enough for our healthcare professionals who present self sacrifice on these difficult days.

The situation with the Coronavirus/COVID-19 is, as I’m sure you’re aware, constantly evolving. Our senior management team are meeting regularly to review the guidance we receive and the advice we give. We have also updated our procedures to ensure we are able to honour our commitments to our team and our customers. Our intention at this time is to maintain an uninterrupted supply chain, this will include functioning production, order processing and technical departments, along with a customer service support team.

The collaboration between EMA and FDA formally started in 2003 and the two agencies have now almost daily interactions, most of them structured around working groups called 'clusters', some of which include contacts with other international regulators, with the aim to better align, and advance scientific and regulatory excellence worldwide. In the context of the COVID-19 pandemic, the EC, EMA and FDA have further intensified their collaboration through regular interactions, notably under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA).